Purified anti-SARS-CoV-2 Nucleocapsid Antibody, SARS-CoV-2, A20087H,BioLegend,946101
SARS-CoV-2 is 90% homologous to SARS-CoV. Cross reactivity of anti-SARS-CoV-2 Nucleocapsid antibody (clone A20087H) with SARS-CoV has not been tested.BioLegend offers two clones specific for SARS-CoV-2 nucleocapsid, clones A20087F and A20087HBoth clones have been verified for western blot, with A20087F showing a higher affinity for SARS-CoV-2 nucleocapsid for this applicationBoth clones have been verified for direct ELISA and displayed similar EC50values for this applicationA20087H has been verified for ICFC, while A20087F is not recommended for this application
Host
Mouse
Reactivity
SARS-CoV-2
Application
WB - Quality testedDirect ELISA, ICFC - Verified
Platform ID
BAB990160341

BioLegend
Contact
Tel: 1-858-455-9588
Fax: +49 (4131) 7023913
Email:
Specifications
Scientific Background
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a single stranded RNA virus that belongs in a family of viruses known as coronaviruses. SARS-CoV-2 infection, known as COVID-19, was declared a pandemic in 2020 and among other symptoms leads to respiratory infection, pulmonary failure which can be fatal. SARS-CoV-2 is structurally composed of 4 main proteins (e.g. spike glycoprotein, envelope glycoprotein, membrane glycoprotein and nucleocapsid protein) and several accessory proteins.The SARS-CoV-2 Nucleocapsid (N) is an abundant protein, that binds to the viral RNA and helps stabilize it. It has been proposed that N protein forms bimolecular condensates that both regulate viral replication and modulate the host response to the virus following infection. N protein is a major antigen that the host immune response is directed to following SARS CoV-2 infection making it a promising candidate for vaccine development and drug therapy.
Category Paths
Please provide the required information below so that we can quickly source your products.
